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Background and Objectives
The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare
single non-myeloablative intensive treatment with double, intensive treatment in  pre-
viously untreated patients with multiple myeloma (MM).
Design and Methods
Three hundred and three patients with stage II/III  MM were randomized after VAD
induction chemotherapy to receive two cycles of non-myeloablative intermediate-dose
melphalan (70 mg/m2) (single treatment) or the same regimen followed by cyclophos-
phamide 120 mg/kg iv plus total body irradiation (TBI) 9 Gy and autologous stem cell
transplantation (double, intensive treatment). In both treatment arms interferon αIIa
was given as maintenance until relapse/progression.
Results
A significantly higher proportion of patients achieved a complete remission (CR) on
protocol treatment with double, intensive therapy (32% vs 13%, p<0.001). Double
treatment produced better outcome in terms of event-free survival (median 22 vs  21
months, 28% vs 14% at 4 years and 15% vs 7% at 6 years after randomization;
logrank p=0.013; univariate HR 0.74, 95% CI, 0.58-0.94), progression-free survival
(median 27 vs 24 months, 33% vs 16% at 4 years, and 17% vs 9% at 6 years after
randomization; logrank p=0.006; HR=0.71, 95% CI 0.56-0.91), but not overall sur-
vival (median 50 vs 55 months, 52% vs 56% at 4 years and 39% vs 36% at 6 years
after randomization; logrank p=0.51; HR=1.10, 95% CI 0.83-1.46). The achievement
of a CR had a favorable prognostic impact on event-free survival (HR=0.60, 95%
CI=0.44 -0.82, p=0.001) and progression-free survival (HR=0.62, 95% CI=0.45 -
0.84, p=0.002). 
Interpretation and Conclusions
Double, intensive treatment resulted in a  better CR rate, event-free survival and pro-
gression-free survival but not overall survival compared to single non-myeloablative
treatment in previously untreated patients with multiple myeloma.
Key words: intermediate dose, melphalan, myeloablative treatment, HOVON 24 trial.
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The prognosis of younger patients with multiplemyeloma (MM) has improved since the intro-duction of high-dose melphalan followed by
autologous stem cell rescue in first-line treatment.1-5
Randomized clinical trials have shown that high-dose
therapy supported by autologous stem cell transplanta-
tion (SCT) has a superior outcome compared to con-
ventional chemotherapy.2,6,7 Other non-randomized tri-
als have demonstrated that the achievement of com-
plete remission (CR) is strongly correlated with longer
survival.8,9 In order to increase the proportion of
patients achieving CR, the concept of repeated high-
dose treatment has been applied (tandem transplanta-
tion).10 In a French randomized trial, single therapy was
compared to double high-dose therapy. There were
higher rates of very good partial responses and com-
plete responses in patients with double transplantation,
and a doubling of the 7-year probability of event-free
survival (EFS) and overall survival (OS) in the whole
patient population although the greatest benefits were
seen in patients who failed to achieve at least a very
good partial response (VGPR) after the first transplant.9
The Dutch-Belgian HOVON group performed a ran-
domized phase 3 trial to compare single maximum
dose non-myeloablative (semi-intensive) treatment
(subsequently referred to as single treatment) with the
same regimen followed by myeloablative high-dose
therapy in previously untreated patients with MM. In
this trial, single non-myeloablative treatment consisted
of intravenous melphalan 140 mg/m2, divided into two
cycles of 70 mg/m2, which was administered without
stem cell rescue in the outpatient clinic. Patients who
had been randomized to double treatment were treat-
ed with additional high-dose cyclophosphamide plus
total body irradiation (TBI) and autologous SCT.
Maintenance treatment with interferon αIIa was given
in both arms. 
Design and Methods
Patients
Patients aged 18 to 65 years with previously untreated
MM, stage II or III A/B disease according to the Salmon
and Durie criteria were eligible for registration.11 Criteria
for exclusion were WHO performance status >3, severe
cardiac, pulmonary, neurological or organ dysfunction
WHO>2, inadequate liver function (i.e. bilirubin ≥2.5
times the upper limit of normal value), prior or concomi-
tant malignant disease except non-melanoma skin
tumors or stage 0 cervical carcinoma, and prior extensive
radiotherapy to the spinal cord or central nervous system
which could preclude total body irradiation. In patients
with myeloma–related renal failure, hemodialysis was
performed during VAD treatment as needed. Treatment
for hypercalcemia with pamidronate was administered
when indicated. Patients received antibacterial and anti-
fungal prophylaxis according to institutional guidelines
and monthly intravenous pamidronate for the duration
of the study.  
All patients had given written informed consent before
inclusion. The study was performed according to the
Helsinki agreement. The trial was approved by the pro-
tocol review committee of the Dutch National Cancer
League CKTO and by the local ethics committees of all
participating hospitals.
Randomization
Patients were randomly assigned to receive single or
double (intensive) treatment. The randomization was
performed immediately after induction chemotherapy
(VAD), irrespective of the patients’ response to VAD.
Randomization was stratified by center. Exclusion crite-
ria for randomization were WHO performance status 3-
4, severe cardiac disease, inadequate liver function or
persistent serum creatinine ≥177 umol/L. Patients under
56 years of age with an HLA-identical sibling were can-
didates for allogeneic SCT, in which case they were not
eligible for randomization.
Treatment
Patients were treated with three or four cycles of VAD
(daily vincristine 0.4 mg and doxorubicin 9 mg/m2)
administered as short time intravenous infusion for 4
consecutive days with oral dexamethasone 40 mg on
days 1-4, 9-12 and 17-20 during uneven cycles and on
days 1-4 during even cycles).12 Treatment cycles were
repeated at 4-weekly intervals. Following VAD, patients
were randomly assigned to receive single or double treat-
ment, irrespective of their response to VAD except in
case of persisting renal failure.
The outline of randomization and treatment is present-
ed in Figure 1. Peripheral blood stem cells were collected
following high-dose cyclophosphamide (4 g/m2) plus
granulocyte colony-stimulating factor (G-CSF) as
described previously.12
Registration
R
3-4 VAD push
Cyclophosphamide
4g/m2 + G-CSF
Cyclophosphamide
4g/m2 + G-CSF
Melphalan 2×70
mg/m2
Melphalan 2×70
mg/m2
Cy/TBI + ASCT
Interferon 3×106 IU
s.c. 3x/week
Interferon 3* 106 IU
s.c. 3×/week
N=441
N=148
N=146
N=142
N=97
N=153
N=153
N=116
N=80
N=155
Figure 1. Flow diagram of patients included in the trial. 
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Single non-myeloablative (semi-intensive) treatment
Melphalan (140 mg/m2) was administered in two intra-
venous administrations of 70 mg/m2 at a 6-8 week inter-
val without stem cell reinfusion.13 Prophylactic G-CSF
(filgrastim, Neupogen) was started on day +4 after mel-
phalan at a daily dose of 300 to 480 µg subcutaneously
until the neutrophil count had recovered to ≥1.0×109/L.
Double treatment
Patients who were randomized to the double treat-
ment proceeded to this regimen if they had achieved at
least a partial remission and if an adequate stem cell graft
was available. The second, high-dose treatment was
based on a myeloablative conditioning regimen consist-
ing of cyclophosphamide 120 mg/kg iv in 2 days fol-
lowed by total body irradiation (TBI) with lung shielding
(9 Gy, lung dose 8 Gy). Maintenance treatment with
interferon αIIa (IFN, 3×106 units thrice weekly) was start-
ed in both treatment groups at 60 to 90 days after mel-
phalan (single) or cyclophosphamide/TBI (double) treat-
ment and was continued until relapse or progression.12
Response evaluation
The response to treatment was monitored by means of
serum immune-electropheresis and immunofixation,
which were carried out after each treatment cycle and at
3-month intervals during the follow-up. Bone marrow
aspirates were taken at diagnosis and after high-dose
treatment or when needed to confirm complete
response. Response assessments were performed accord-
ing to modified criteria of the European Group for Blood
and Bone Marrow Transplantation (EBMT).14 A complete
response was defined as the absence of monoclonal
immunoglobulins in serum or urine by immunofixation
and in addition absence of monoclonal plasma cells in
the bone marrow by light chain immunophenotyping. 
Statistical analysis
The first analysis of the randomization was performed
in November 2001, as previously described.12 Here we
report the long-term results. The primary end-point of
the trial was event-free survival (EFS) from randomiza-
tion, and the study was designed to detect, with a statis-
tical power of 80% and a two-sided significance level
α=0.05, a 15% increase in 2-year EFS from 40% to 55%
in the double treatment arm. Secondary end-points were
CR rate, progression-free survival (PFS) and overall sur-
vival (OS). EFS was calculated from the date of random-
ization until not at least a PR after high-dose melphalan,
progression/relapse after previous response or death
without progression, whichever came first. Data on
patients who had no events were censored at the time of
last contact. In patients who did not achieve at least a PR
after high-dose melphalan, treatment was considered to
have failed at day 1 after randomization. PFS was deter-
mined from randomization until progression/relapse or
death, whichever came first. OS was measured from the
date of randomization until death; patients still alive at
the time of last contact were then censored. For the cur-
rent analysis, the data were used as available of
November 7, 2006. The characteristics of the patients in
the two treatment arms were compared using Pearson’s
χ2 test or Fisher’s exact test whichever was appropriate,
in the case of discrete variables, or the Wilcoxon rank-
sum test in case of continuous variables. The CR rate was
compared between the two arms using logistic regres-
sion analysis15 and an odds ratio (OR) with a 95% confi-
dence interval (CI) was calculated. EFS, PFS and OS were
estimated by the Kaplan-Meier method.16 Kaplan-Meier
curves were generated to illustrate differences between
the two treatment arms and compared using the log-rank
test.17 Cox regression analysis was used to evaluate the
impact of treatment arm when other prognostic factors
were also included.18 Hazard ratios and 95% CI were
constructed. The following baseline characteristics were
included in the regression analyses: age, stage according
to Salmon and Durie (II vs. III), Ig isotype (IgA vs other),
hemoglobin, β2-microglobulin (natural logarithm) and
lactate dehydrogenase(LDH)/upper normal limit (UNL)
(natural logarithm). In the multivariate analyses, missing
baseline characteristics were imputed using a single-
imputation method, i.e. conditional mean imputation
based on the other available variables.19 The impact of
reaching a CR on EFS, PFS and OS from randomization
was evaluated with Cox regression, using CR as a time-
dependent co-variate. The analyses were performed
according to the intention-to-treat principle, i.e. patients
who were eligible for randomization were analyzed
according to the treatment arm they were assigned to.
All reported p-values are two-sided and a significance
level α=0.05 was used.
Results
Patients’ characteristics and treatment received
Overall, 453 patients were registered from 46 hematol-
ogy centers in the Netherlands and Belgium over a peri-
od from November 1995 to March 2000; of these
patients, 12 were not eligible for inclusion in this study.
Sixty-three patients with an HLA identical sibling donor
proceeded to allogeneic transplantation and were not,
therefore, randomized; their results have been reported
elsewhere.20 Another 75 patients were not randomized
because of early death (n=16), poor performance status
(n=17), renal failure (n=8), patients’ refusal (n=7), non-eli-
gibility (n=8) or other (n=19). A total of 303/441 patients
(69%) were randomized and were included in this analy-
sis: 148 for single and 155 for double intensive therapy.
The characteristics of the randomized patients are listed
in Table 1. The myeloma subtypes, level of β-2-
microglobulin, Salmon and Durie stage and age were not
different between the two treatment arms. The actual
treatment given is summarized in Figure 1. In treatment
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arm A (single treatment) 25 patients received only one
administration of melphalan, 117 received both melpha-
lan administrations and 97 patients started on IFN main-
tenance. In arm B (double), 25 patients received only one
dose of melphalan, 128 received two doses, 116 patients
completed the second, high-dose treatment with autolo-
gous SCT and 80 started with IFN maintenance. The sec-
ond intermediate-melphalan dose cycle was not adminis-
tered in 50 patients, most frequently due to toxicity
(34%) or resistance/progression after the first dose
(n=18), while the exact reason was unknown in 17
patients (34%). One patient had to be rescued with
autologous SCT after melphalan because of incomplete
hematologic recovery. IFN maintenance was stopped
prematurely because of toxicity in 33 of 97 (34%)
patients randomized to single treatment and in 53 of 80
(66%) of patients who received the double treatment.
The duration of IFN maintenance treatment was not dif-
ferent between the treatment groups, being a median of
7 months in the double treatment arm vs 12 months in
the single treatment arm (logrank p=0.52 ). 
Table 1. Patients’ characteristics.
Single Double Total
Total (#) 148 155 303
Sex
Male 85 98 183
Female 63 57 120
Median age (yr, range) 55 (37-65) 56 (32-65) 56 (32-65)
≤55 76 69 145
56-60 43 53 96
61-65 29 33 62
WHO PF status
0 63 54 117
1 58 128
≥2 27 31 58
Salmon & Durie stage
2A 38 36 74
2B 0 2 2
3A 101 107 208
3B 9 10 19
Hemoglobin (mmol/L)
Median (range) 6.8 (3.9-9.8) 7.0 (3.4-10) 6.9 (3.4-10.0)
≤6.2 53 43 96
>6.2 95 112 207
Serum calcium (mmol/L)
Median (range) 2.4 (1.1-4.0) 2.4 (1.7-3.7) 2.4 (1.1-4.0)
≤2.65 122 137 259
>2.65 24 16 40
Serum β-2-microglobulin (mg/L)
Median (range 2.9 (0.4-58.0) 3.0 (0.1-14.1) 3.0 (0.1-58.0)
≤3.0 64 72 136
>3.0 55 70 125
M-protein
IgA 41 39 80
IgG 84 93 177
IgD 4 3 7
Light chain disease 14 14 28
Non/oligosecretory 5 6 11
Serum lactodehydrogenase
LDH /ULN, median (range) 0.7 (0.1-11.9) 0.7 (0.2-2.1) 0.7 (0.1-11.9)
Normal 114 122 236 
Elevated 24 19 43
ULN: upper limit of normal value.
Table 2. Response according to randomization arm.
Single Double Total
Patients [N.] 148 155 303
CR on protocol treatment (p<0.001)
No 129 (87%) 106 (68%) 235 (78%)
Yes 19 (13%) 49 (32%) 68 (22%)
Cumulative CR rate following subsequent treatments*
VAD 1 (1%) 6 (4%) 7 (2%)
HDM 14 (9%) 27 (17%) 41 (14%)
ASCT − 40 (26%) 54 (18%)
IFN 19 (13%) 49 (32%) 68 (22%)
In follow-up 26 (18%) 52 (34%) 78 (26%)
VAD: vincristine, doxorubicin and dexamethasone; HDM: high-dose melphalan;
ASCT: autologous stem cell transplantation; IFN: interferon-α.*The table indicates the
number and percentage of patients who achieved a CR after the different treatment
phases. For example, from the 7 patients with CR after VAD and 41 patients with CR after
high-dose melphalan, it can be concluded that HDM resulted in a CR in 41 – 7 = 34
patients.
P. Sonneveld et al. 
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Response
The response data are presented in Table 2. An objec-
tive response (PR or CR) after melphalan was achieved in
267/303 (88%) patients. An evaluation at the end of
chemotherapy and before the start of maintenance
showed that the complete response rate was significant-
ly higher in patients given double treatment than in those
given single treatment (26% vs 9%, p<0.001). During
maintenance, the CR rate increased to 32% in the double
treatment group and 13% in the single treatment group
(p<0.001). Prognostic factors associated with a higher CR
rate were Salmon and Durie stage 3, a higher hemoglo-
bin and lower serum β2-microglobulin level.
Event-free survival 
The median EFS from randomization was 21 months
with single treatment vs 22 months with double treat-
ment. Actuarial probabilities at 4 and 6 years were 28%
and 15% in the double treatment versus 14% and 7% in
the single treatment arm (logrank p=0.014 ) (Figure 2).
The univariate hazard ratio (HR) for treatment arm was
0.74 (95% CI, 0.58-0.94). Similar results were obtained
when adjusted for baseline characteristics (Table 3).
Significant negative prognostic factors for EFS in the Cox
regression analysis were higher age, IgA isotype and
lower hemoglobin concentration. 
Progression-free survival 
The median PFS from randomization was 24 months
with single treatment (16% at 4 years and 9% at 6 years)
versus 27 months (33% at 4 years and 17% at 6 years)
with double treatment (logrank p=0.006; HR=0.71, 95%
CI 0.56-0.91). The effect of treatment arm remained sta-
tistically significant when adjusted for baseline covari-
ates (Table 3). Significant negative prognostic factors for
PFS in the Cox regression analysis were higher age, IgA
isotype, lower hemoglobin and higher LDH/ULN values. 
Overall survival
As of November 7, 2006, 213 of 303 patients (70%)
had died: 105 in the single treatment group and 108 in
Figure 2. Kaplan-Meier survival curves. (A) event-free survival, (B)
progression-free survival and (C) Overall survival. 
Table 3. Multivariate analysis by Cox regression.
Event-free survival
Co-variate HR 95% CI p value
Treatment arm 0.73 0.57-0.93 0.01
Age 1.03 1.01-1.05 0.008 
Salmon and Durie stage 3 1.22 0.92 -1.62 0.17 
IgA (vs. other isotype) 1.42 1.08 -1.87 0.01
Hemoglobin 0.86 0.76-0.96 0.01 
Log(β2-microglobulin) 1.17 0.94 -1.46 0.17 
Log(LDH/ULN) 1.22 0.97 -1.52 0.09 
Progression-free survival
Co-variate HR 95% CI p value
Treatment arm 0.69 0.54-0.88 0.003 
Age 1.03 1.01-1.05 0.005 
Salmon and Durie stage 3 1.26 0.95 -1.67 0.12
IgA (vs. other isotype) 1.67 1.27 -2.20 <0.001
Hemoglobin 0.82 0.73 -0.92 <0.001
Log(β2-microglobulin) 1.17 0.93 -1.49 0.18 
Log(LDH/ULN) 1.25 1.01 -1.56 0.04 
Overall survival
Co-variate HR 95% CI p value
Treatment arm 1.06 0.81 -1.40 0.66 
Age 1.04 1.02-1.07 < 0.001 
Salmon and Durie stage 3 1.41 1.00 – 1.97 0.05 
IgA (vs. other isotype) 1.61 1.19 -2.19 0.002 
Hemoglobin 0.76 0.67 -0.87 <0.001
Log(β2-microglobulin) 1.19 0.92 -1.54 0.18 
Log(LDH/ULN) 1.36 1.06 -1.75 0.02
A
N E
Single 148 139
Double 155 134
N E
Single 148 139
Double 155 132
Single148 60 21 11 4 1
Double155 74 44 23 12 2
Single148 71 24 13 4 1
Double155 85 51 24 12 2
Single
Double
Single
Double
N D
Single 148 105
Double 155 108
Single
Double
0 24 48 72 98 months 120
0 24 48 72 98 months 120
At risk:
At risk:
Single148 117 82 51 21 5
Double155 109 81 57 23 3
0 24 48 72 98 months 120
At risk:
100
75
50
25
0
100
75
50
25
0
100
75
50
25
0
B
C
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the double treatment group. The median follow-up from
randomization of the 90 patients still alive was 92
months (range, 17-129). The median survival was 55
months in the single treatment group and 50 months in
the double treatment group. Actuarial probabilities at 4
and 6 years were 52% and 39%, respectively, in the dou-
ble treatment group versus 56% and 36%, respectively,
in the single treatment arm (logrank p=0.81; HR=1.03,
95% CI 0.79-1.35). A similar result was obtained when
the analysis was performed with adjustment for baseline
covariates (Table 3). 
Negative prognostic factors for PFS were also predic-
tive for worse overall survival. Of note, 45 (30%) patients
who relapsed after single treatment were salvaged by
high-dose therapy with stem cell support, as compared
with only six (4%) patients treated with double treat-
ment. The Kaplan-Meier survival curves are depicted in
Figure 2. It should be noted that with 213 deaths among
303 patients, the study had 83% power to detect only a
HR of 0.67, which is equivalent to an improvement in
(median) OS of 50%. The power to detect a smaller, but
clinically still relevant, improvement in OS was, there-
fore, limited.
Prognostic value of CR
Univariate Cox regression analysis indicated that
obtaining a CR during treatment had a favorable prog-
nostic impact on EFS (HR=0.60, 95% CI=0.44-0.82,
p=0.001) and PFS (HR=0.62, 95% CI=0.45-0.84, p=0.002)
but not on OS (HR=0.81, 95% CI=0.57-1.13, p=0.21).
These results remained very similar when treatment arm
was also included and are, therefore, not shown.
Causes of death
At the time of analysis, 105/148 ( 71%) patients in the
single treatment group had died as compared to 108/155
(70%) in the double treatment. Active myeloma was the
primary cause of death in 82/105 in the single treatment
arm (78%), and in 86/108 in the double, intensive arm
(80%). Treatment-related mortality was 6/148 (4%) in
the single treatment arm and 16/155 (10%) in the double,
intensive arm
Discussion
The introduction of high-dose therapy supported by
autologous SCT has significantly improved the prognosis
of patients with active MM.1,2,4,6,7,12,13,21-28 Several random-
ized trials have investigated whether high-dose therapy
is superior to conventional chemotherapy.2,6,28-31 The
Nordic Study Group found that high-dose therapy had a
superior impact on survival compared with treatment in
historic controls27 and in two prospective trials.2,6 In con-
trast, the Spanish Pethema study demonstrated a higher
CR rate, but no impact of high-dose therapy on PFS and
OS compared with conventional chemotherapy.29 A
study from the Groupe Myelome-Autogreffe showed an
effect on EFS but not OS, while the US Intergroup Trial
S9321 failed to demonstrate an effect of high-dose thera-
py on response rates or survival.28,31 Most treatment pro-
tocols use high-dose treatment as part of the initial ther-
apy, although others have shown that the effect of sal-
vage transplantation may be equal to transplantation
upfront.7
The overall picture from these trials is that high-dose
therapy improves the response rate as well as EFS or PFS
but that the effect on survival differs. Even with high-
dose treatment upfront, the majority of patients will ulti-
mately relapse and a further intensification may, there-
fore, be considered in order to improve the quality of the
initial response. The concept of repeated intensive treat-
ment was pioneered in the total therapy 1 and 2 pro-
grams.8,32 The French IFM group showed, in a random-
ized trial, that double high-dose treatment followed by
autologous SCT improves the PFS in patients who do not
achieve a very good partial response or complete
response with one intensive treatment.9 In addition, the
Bologna study also showed superior CR, EFS and OS
rates although a final analysis has not yet been pub-
lished.33 In another trial from the IFM group in high-risk
patients, repeated high-dose melphalan was not found to
have a significant effect on OS.34
With our trial we wanted to compare intermediate-
dose melphalan as non-myeloablative semi-intensive
treatment (single treatment) with the same regimen fol-
lowed by high-dose therapy and autologous stem cell
transplantation (double treatment). Intermediate-dose
melphalan was designed as two non-myeloablative,
intravenous doses of melphalan of 70 mg/m2 each. This
dose is lower than that reported by others35 and is based
on our previous phase II trial,36 in an attempt to achieve
intensive therapy without restricting the availability of
autologous stem cells. Concerning this trial, we previous-
ly reported that with a short follow-up (median 33
months) no difference was observed between these two
treatments in myeloma.12 However, with longer follow-
up (median almost 8 years) a small but significant differ-
ence was observed for PFS, but not OS. The difference
became evident late (>4 years) after treatment. Also, the
number of complete responses was higher following
double treatment and improved even further during
maintenance treatment. Patients who achieved a CR had
a better probability of EFS and PFS. The results of this
study illustrate that the benefit of repeated (intensive)
treatment during front-line therapy is restricted to a bet-
ter CR rate and PFS. No significant effect on OS was
achieved with this approach. This may also confirm that
the use of TBI as a myeloablative preparative regimen for
autologous SCT in myeloma is not very effective and
should be omitted. Moreau et al. demonstrated that the
efficacy of TBI used after high-dose melphalan in tandem
transplantation may be limited.37 The French IFM group
has proposed that tandem transplantation is the pre-
P. Sonneveld et al. 
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ferred treatment in (high-risk) patients who fail to
achieve at least a very good PR or a CR with a single
autologous transplant.9,34,37 This approach is based on the
finding that the achievement of CR is an important
favorable prognostic factor for durable responses.38
However, it remains to be determined whether repeated
high-dose treatment is the best approach for accomplish-
ing CR. Finally, the lack of efficacy of interferon and the
poor patient compliance in this and other trials under-
lines that this compound has become obsolete in the
treatment of myeloma.39
The introduction of novel agents such as thalidomide
and bortezomib has demonstrated that higher CR rates
are possible in relapsed patients and in front-line treatment
with remission induction chemotherapy.40-43 Combi-
nations of these drugs with high-dose treatment may pro-
vide a new opportunity to improve the treatment results
in MM.26,32,40,44 In view of the lack of improvement of OS
following double intensive treatment, these new agents
must be introduced in front-line therapy, and consequent-
ly the role of double intensive treatment needs to be re-
evaluated. It remains to be established, however, what the
long-term outcome will become in patients who receive
these agents as part of their front-line therapy, since it has
been shown that rescue treatment may be less effective in
patients who are continuously exposed to thalidomide.45
Thalidomide and bortezomib are currently being investi-
gated as part of induction therapy prior to high-dose ther-
apy and maintenance in two HOVON trials and several
international studies. 
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